Outcome according to conditioning regimen
| . | FLU/THIO/BU . | FLU/THIO/TREO . | P value . |
|---|---|---|---|
| Patients | 180 | 128 | |
| Death, evaluable in | 180 | 128 | |
| Deaths, n | 54 | 38 | .977 |
| 3-y OS (95% CI) | 0.71 (0.64-0.77) | 0.72 (0.63-0.79) | |
| Any event, evaluable in | 180 | 128 | |
| Events, n | 76 | 58 | .626 |
| 3-y EFS (95% CI) | 0.60 (0.53-0.67) | 0.55 (0.46-0.63) | |
| Relapse, evaluable in | 180 | 128 | |
| Relapses, n | 60 | 45 | .779 |
| 3-y CIR (95% CI) | 0.31 (0.25-0.38) | 0.36 (0.27-0.44) | |
| NRM, evaluable in | 180 | 128 | |
| NRM, n | 16 | 12 | .831 |
| 3-y NRM (95% CI) | 0.08 (0.05-0.13) | 0.09 (0.05-0.15) | |
| SM, evaluable in | 180 | 128 | |
| SMs, n | 0 | 1 | .487 |
| 3-y SM (95% CI) | 0.00 (.-.) | 0.00 (.-.) | |
| aGVHD at day 100, evaluable in | 178 | 124 | |
| Grade 0 or 1, n (%) | 127 (42%) | 96 (32%) | .238 |
| Grade 2, n (%) | 35 (12%) | 15 (5%) | |
| Grade 3 or 4, n (%) | 16 (5%) | 13 (4%) | .664 |
| aGVHD, any time, evaluable in | 178 | 126 | |
| Grade 0 or 1, n (%) | 116 (38%) | 95 (31%) | |
| Grade 2, n (%) | 40 (13%) | 13 (4%) | |
| Grade 3 or 4, n (%) | 22 (7%) | 18 (6%) | |
| aGVHD grade 2, 3, or 4 at 1-y (95% CI) | 0.32 (0.25-0.39) | 0.25 (0.17-0.32) | .074 |
| cGVHD, evaluable in | 180 | 128 | |
| Limited cGVHD, n | 17 | 10 | |
| At 3-y (95% CI) | 0.09 (0.06-0.14) | 0.08 (0.04-0.13) | .593 |
| Extensive cGVHD, n | 19 | 6 | |
| At 3-y (95% CI) | 0.11 (0.07-0.16) | 0.05 (0.02-0.09) | .065 |
| Any cGVHD, n | 36 | 16 | |
| At 3-y (95% CI) | 0.20 (0.15-0.26) | 0.13 (0.08-0.19) | .077 |
| Competing events, n | 66 | 52 | |
| 3-y CICE (95% CI) | 0.34 (0.27-0.41) | 0.40 (0.32-0.49) | |
| GRFS, evaluable in | 180 | 128 | |
| GRFS, n | 97 | 70 | |
| 3-y GRFS (95% CI) | 0.48 (0.41-0.55) | 0.45 (0.37-0.54) | .890 |
| Nonhematological AE until day 100 | 179 | 128 | |
| Grade 3 or 4, n (%) | 132 (73%) | 105 (82%) | .088 |
| . | FLU/THIO/BU . | FLU/THIO/TREO . | P value . |
|---|---|---|---|
| Patients | 180 | 128 | |
| Death, evaluable in | 180 | 128 | |
| Deaths, n | 54 | 38 | .977 |
| 3-y OS (95% CI) | 0.71 (0.64-0.77) | 0.72 (0.63-0.79) | |
| Any event, evaluable in | 180 | 128 | |
| Events, n | 76 | 58 | .626 |
| 3-y EFS (95% CI) | 0.60 (0.53-0.67) | 0.55 (0.46-0.63) | |
| Relapse, evaluable in | 180 | 128 | |
| Relapses, n | 60 | 45 | .779 |
| 3-y CIR (95% CI) | 0.31 (0.25-0.38) | 0.36 (0.27-0.44) | |
| NRM, evaluable in | 180 | 128 | |
| NRM, n | 16 | 12 | .831 |
| 3-y NRM (95% CI) | 0.08 (0.05-0.13) | 0.09 (0.05-0.15) | |
| SM, evaluable in | 180 | 128 | |
| SMs, n | 0 | 1 | .487 |
| 3-y SM (95% CI) | 0.00 (.-.) | 0.00 (.-.) | |
| aGVHD at day 100, evaluable in | 178 | 124 | |
| Grade 0 or 1, n (%) | 127 (42%) | 96 (32%) | .238 |
| Grade 2, n (%) | 35 (12%) | 15 (5%) | |
| Grade 3 or 4, n (%) | 16 (5%) | 13 (4%) | .664 |
| aGVHD, any time, evaluable in | 178 | 126 | |
| Grade 0 or 1, n (%) | 116 (38%) | 95 (31%) | |
| Grade 2, n (%) | 40 (13%) | 13 (4%) | |
| Grade 3 or 4, n (%) | 22 (7%) | 18 (6%) | |
| aGVHD grade 2, 3, or 4 at 1-y (95% CI) | 0.32 (0.25-0.39) | 0.25 (0.17-0.32) | .074 |
| cGVHD, evaluable in | 180 | 128 | |
| Limited cGVHD, n | 17 | 10 | |
| At 3-y (95% CI) | 0.09 (0.06-0.14) | 0.08 (0.04-0.13) | .593 |
| Extensive cGVHD, n | 19 | 6 | |
| At 3-y (95% CI) | 0.11 (0.07-0.16) | 0.05 (0.02-0.09) | .065 |
| Any cGVHD, n | 36 | 16 | |
| At 3-y (95% CI) | 0.20 (0.15-0.26) | 0.13 (0.08-0.19) | .077 |
| Competing events, n | 66 | 52 | |
| 3-y CICE (95% CI) | 0.34 (0.27-0.41) | 0.40 (0.32-0.49) | |
| GRFS, evaluable in | 180 | 128 | |
| GRFS, n | 97 | 70 | |
| 3-y GRFS (95% CI) | 0.48 (0.41-0.55) | 0.45 (0.37-0.54) | .890 |
| Nonhematological AE until day 100 | 179 | 128 | |
| Grade 3 or 4, n (%) | 132 (73%) | 105 (82%) | .088 |
aGVHD grading according to Glucksberg criteria; limited cGVHD: involvement of liver, skin, or both; extensive cGVHD: involvement of liver and/or skin plus any other organ.
95% CI, 95% confidence interval; CICE, cumulative incidence of competing events; SM, secondary malignancy.